{"id":496139,"date":"2021-05-20T06:03:09","date_gmt":"2021-05-20T10:03:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/"},"modified":"2021-05-20T06:03:09","modified_gmt":"2021-05-20T10:03:09","slug":"positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/","title":{"rendered":"Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistcircle { list-style-type: circle }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig<sup>\u00ae<\/sup>) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting<\/b><\/p>\n<p class=\"bwalignc\"><i>&#8211; OPTIC trial evaluating response-based dosing regimens of ponatinib in patients with resistant CP-CML met primary endpoint, confirming optimal benefit-risk profile achieved via 45mg\/day starting dose reduced to 15mg\/day upon response <\/i><\/p>\n<p>WILMINGTON, Del.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nIncyte (Nasdaq:INCY) today announced that data from the primary analysis of the Phase 2 OPTIC (<b>O<\/b>ptimizing <b>P<\/b>onatinib <b>T<\/b>reatment <b>I<\/b>n <b>C<\/b>ML) trial will be presented during an oral session (Abstract #7000) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually June 4-8, 2021. The OPTIC trial \u2013 an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ponatinib (Iclusig<sup>\u00ae<\/sup>) over a range of three starting doses (45mg, 30mg, 15mg) followed by dose reduction to 15mg with the aim of optimizing efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant to prior tyrosine kinase inhibitor (TKI) therapy \u2013 met its primary endpoint.\n<\/p>\n<p>\nThe trial, sponsored by Takeda and co-funded by Incyte, evaluated treatment in patients with resistant disease, with and without mutations. The results show that the optimal benefit-risk profile for ponatinib in patients with CP-CML was achieved with a starting dose of 45mg\/day, and upon response (achieving \u22641% BCR-ABL1<sup>IS<\/sup>), dose reduction to 15mg\/day. The results also suggest a clinically-manageable safety profile for ponatinib. Data from the OPTIC interim analysis (cutoff date of July 2019), which evaluated 216 patients with a median follow-up of 21 months, were <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.incyte.com%2Fpress-releases%2Fpress-releases%2F2020%2FInterim-Data-from-the-Open-Label-Phase-2-OPTIC-Study-of-Iclusig-ponatinib-for-Chronic-Phase-CML-Presented-at-the-ASCO-and-EHA-Virtual-Meetings%2Fdefault.aspx&amp;esheet=52432605&amp;newsitemid=20210520005174&amp;lan=en-US&amp;anchor=previously+reported&amp;index=1&amp;md5=fded00cdc41949f14976d4224025d8a0\">previously reported<\/a>. The primary analysis (cutoff date of May 2020) evaluated 283 patients with a median follow-up of 32 months. All patients in the OPTIC trial were evaluable for the primary endpoint at the time of this analysis.\n<\/p>\n<p>\n\u201cThe OPTIC primary analysis reinforces the positive response that is achievable with ponatinib in appropriate patients with CP-CML, and the ability that response-based regimens have to maximize efficacy, while maintaining a manageable safety profile,\u201d said Luca Marini, M.D., Regional Vice President, Head of European Medical Affairs, Incyte. \u201cThe OPTIC trial provides additional confirmation on the optimization of ponatinib dosing and reinforces its role as a meaningful treatment option for patients.\u201d\n<\/p>\n<p>\nKey findings from the OPTIC primary analysis include:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe maximum rates of \u22641% BCR-ABL1<sup>IS<\/sup> at 12 months, the primary endpoint, were achieved in the 45mg\/day starting dose cohort (44.1%), and 73.3% of patients in this cohort maintained response with the dose reduction to 15mg\/day. The 30mg\/day and 15mg\/day starting dose cohorts also demonstrated benefit (29.0% and 23.1% \u22641% BCR-ABL1<sup>IS<\/sup> at 12 months, respectively), especially in patients with less-resistant disease and with a T315I mutation.\n<\/li>\n<li>\nPositive survival outcomes were estimated in all three arms, with an 89.3% 36-month overall survival (OS) probability anticipated for the 45mg starting dose cohort and 73.3% progression-free survival (PFS) anticipated for the same cohort.<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nThis indicates that the dose-reduction strategy did not impact OS regardless of prior second-generation TKI resistance or the presence of BCR-ABL1 mutations.\n<\/li>\n<\/ul>\n<\/li>\n<li>\nRates of arterial occlusive events (AOEs) observed at the time of primary analysis (6% overall and 9.6% in the 45mg starting dose cohort) suggest a clinically manageable safety profile.\n<\/li>\n<li>\nSafety data include:<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nAmong all study participants (N=283), the most common treatment-emergent adverse events (TEAEs) Grade 3 or greater were thrombocytopenia (27%), neutropenia (17%) and anemia (7%).\n<\/li>\n<li>\nReported AOEs were 10%, 5% and 3% for the 45mg, 30mg, 15mg\/day starting dose cohorts, respectively. Grade 3 or greater AOEs were 5%, 5% and 3% for the 45mg, 30mg and 15mg\/day starting dose cohorts, respectively.\n<\/li>\n<li>\nReported serious AOEs were 4%, 4% and 3% for the 45mg, 30mg, 15mg\/day starting dose cohorts, respectively. There were four deaths related to AEs (two sudden deaths and two pneumonia).\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n\u201cAs a physician, I am pleased by the results of the OPTIC trial evaluating patients with resistant CP-CML, who are in need of additional options to improve outcomes,\u201d said Dr. Gianantonio Rosti, M.D., Istituto Romagnolo per lo Studio dei Tumori &#8220;Dino Amadori&#8221; (IRST S.r.l.) Istituto di Ricovero e Cura a Carattere Scientifico. \u201cIt is encouraging to see the positive benefit-risk profile that can be achieved with ponatinib through a response-based dosing regimen, therefore providing efficacy while also managing the risk for arterial occlusive events.\u201d\n<\/p>\n<p>\nIncyte has an exclusive license from Takeda Pharmaceuticals International AG to commercialize ponatinib in the European Union and 29 other countries, including Switzerland, UK, Norway, Turkey, Israel and Russia. Iclusig is marketed in the U.S. by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.\n<\/p>\n<p><b>About the OPTIC Trial<\/b><\/p>\n<p>\nOPTIC (<b>O<\/b>ptimizing <b>P<\/b>onatinib <b>T<\/b>reatment <b>I<\/b>n <b>C<\/b>ML) is a randomized, dose-ranging Phase 2 trial designed to evaluate three starting doses (15mg, 30mg, 45mg) of ponatinib in patients with resistant chronic-phase chronic myeloid leukemia (CP-CML) or who had documented history of presence of T315I mutation after receiving any number of prior tyrosine kinase inhibitors (TKIs). Dose reduction at response occurred per study protocol. The trial is expected to inform the optimal use of ponatinib in these patients. The primary endpoint of the trial is achieving \u22641% BCR-ABL1 at 12 months. A total of 283 patients were enrolled at clinical sites around the world. Dose reduction at response occurred per study protocol.\n<\/p>\n<p>\nFor more information about the OPTIC study, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02467270&amp;esheet=52432605&amp;newsitemid=20210520005174&amp;lan=en-US&amp;anchor=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02467270&amp;index=2&amp;md5=d74a1fe08d0f5581850e93a31d60fdf0\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02467270<\/a>.\n<\/p>\n<p><b>About CML <\/b><\/p>\n<p>\nCML \u2013 a rare malignancy \u2013 is one of four main types of leukemia; it is a result of a genetic mutation that takes place in early, immature versions of myeloid cells, which form red blood cells, platelets and most types of white blood cells. Subsequently, an abnormal gene called BCR-ABL1 forms, turning the damaged cell into a CML cell. CML typically progresses slowly, but it can change into a fast-growing acute leukemia that is hard to treat.\n<\/p>\n<p><b>About Ponatinib (Iclusig<sup>\u00ae<\/sup>) Tablets<\/b><\/p>\n<p>\nPonatinib (Iclusig<sup>\u00ae<\/sup>) targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, which has been associated with resistance to other approved TKIs.\n<\/p>\n<p>\nIn the EU, Iclusig is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, or the treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.\n<\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medicines.org.uk%2Femc%2Fmedicine%2F28145%23CONTRAINDICATIONS&amp;esheet=52432605&amp;newsitemid=20210520005174&amp;lan=en-US&amp;anchor=Click+here&amp;index=3&amp;md5=f1490610bbe5b7315a89e46cfa2dd3d0\">Click here<\/a> to view the Iclusig EU Summary of Medicinal Product Characteristics.\n<\/p>\n<p>\nIncyte has an exclusive license from Takeda Pharmaceuticals International AG to commercialize ponatinib in the European Union and 29 other countries, including Switzerland, UK, Norway, Turkey, Israel and Russia. Iclusig is marketed in the U.S. by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.\n<\/p>\n<p><b>About Incyte<\/b><\/p>\n<p>\nIncyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.incyte.com&amp;esheet=52432605&amp;newsitemid=20210520005174&amp;lan=en-US&amp;anchor=Incyte.com&amp;index=4&amp;md5=35e21b5f96d9411e0d13818cc57b76f0\">Incyte.com<\/a> and follow <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FIncyte&amp;esheet=52432605&amp;newsitemid=20210520005174&amp;lan=en-US&amp;anchor=%40Incyte&amp;index=5&amp;md5=72eea3c3b66dc11111a3def12f495a3c\">@Incyte<\/a>.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nExcept for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company\u2019s ongoing clinical development program for ponatinib and the Company\u2019s chronic-phase chronic myeloid leukemia program generally, its clinical development pipeline and whether or when ponatinib or any development compounds will be approved or commercially available for use in the United States or elsewhere for chronic myeloid leukemia program generally or any other indication, its presentation plans for the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.\n<\/p>\n<p>\nThese forward-looking statements are based on the Company\u2019s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company\u2019s clinical trials, supply chain and other third-party providers and development and discovery operations; determinations made by the FDA; the Company\u2019s dependence on its relationships with its collaboration partners; the efficacy or safety of the Company\u2019s products; the acceptance of the Company\u2019s products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; and other risks detailed from time to time in the Company\u2019s reports filed with the Securities and Exchange Commission, including its annual report for the year ended December 31, 2020, and the quarterly report on Form 10-Q for the quarter ended March 31, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005174r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210520005174\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210520005174\/en\/<\/a><\/span><\/p>\n<p><b>Media<br \/>\n<\/b><br \/>Ela Zawislak<br \/>\n<br \/>+41 21 581 5200<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ezawislak@incyte.com\">ezawislak@incyte.com<br \/>\n<\/a><\/p>\n<p>Rachael Remaly Franco<br \/>\n<br \/>+41 21 581 5203<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:rremalyfranco@incyte.com\">rremalyfranco@incyte.com<\/a><\/p>\n<p><b>Investors<br \/>\n<\/b><br \/>Christine Chiou<br \/>\n<br \/>+1 302 274 4773<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:cchiou@incyte.com\">cchiou@incyte.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Delaware Europe United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Other Health Clinical Trials Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210520005174\/en\/1078784\/3\/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting &#8211; OPTIC trial evaluating response-based dosing regimens of ponatinib in patients with resistant CP-CML met primary endpoint, confirming optimal benefit-risk profile achieved via 45mg\/day starting dose reduced to 15mg\/day upon response WILMINGTON, Del.&#8211;(BUSINESS WIRE)&#8211; Incyte (Nasdaq:INCY) today announced that data from the primary analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session (Abstract #7000) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually June 4-8, 2021. The OPTIC trial \u2013 an ongoing, randomized, open-label study prospectively evaluating response-based dosing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-496139","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting &#8211; OPTIC trial evaluating response-based dosing regimens of ponatinib in patients with resistant CP-CML met primary endpoint, confirming optimal benefit-risk profile achieved via 45mg\/day starting dose reduced to 15mg\/day upon response WILMINGTON, Del.&#8211;(BUSINESS WIRE)&#8211; Incyte (Nasdaq:INCY) today announced that data from the primary analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session (Abstract #7000) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually June 4-8, 2021. The OPTIC trial \u2013 an ongoing, randomized, open-label study prospectively evaluating response-based dosing &hellip; Continue reading &quot;Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-20T10:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005174r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting\",\"datePublished\":\"2021-05-20T10:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\\\/\"},\"wordCount\":1566,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210520005174r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\\\/\",\"name\":\"Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210520005174r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-05-20T10:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210520005174r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210520005174r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting - Market Newsdesk","og_description":"Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting &#8211; OPTIC trial evaluating response-based dosing regimens of ponatinib in patients with resistant CP-CML met primary endpoint, confirming optimal benefit-risk profile achieved via 45mg\/day starting dose reduced to 15mg\/day upon response WILMINGTON, Del.&#8211;(BUSINESS WIRE)&#8211; Incyte (Nasdaq:INCY) today announced that data from the primary analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session (Abstract #7000) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually June 4-8, 2021. The OPTIC trial \u2013 an ongoing, randomized, open-label study prospectively evaluating response-based dosing &hellip; Continue reading \"Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-20T10:03:09+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005174r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting","datePublished":"2021-05-20T10:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/"},"wordCount":1566,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005174r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/","name":"Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005174r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-05-20T10:03:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005174r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210520005174r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-primary-analysis-from-the-phase-2-optic-study-of-ponatinib-iclusig-in-chronic-phase-chronic-myeloid-leukemia-cp-cml-to-be-presented-at-the-2021-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig\u00ae) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/496139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=496139"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/496139\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=496139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=496139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=496139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}